Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C53H90O22 |
Molecular Weight | 1079.2685 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 29 / 29 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@@]1(CC[C@]2(C)[C@]1([H])[C@H](O)C[C@]3([H])[C@@]4(C)CC[C@H](O[C@]5([H])O[C@H](CO)[C@@H](O)[C@H](O)[C@H]5O[C@]6([H])O[C@H](CO)[C@@H](O)[C@H](O)[C@H]6O)C(C)(C)[C@]4([H])CC[C@@]23C)[C@](C)(CCC=C(C)C)O[C@@H]7O[C@H](CO[C@@H]8O[C@@H](CO)[C@H](O)[C@H]8O)[C@@H](O)[C@H](O)[C@H]7O
InChI
InChIKey=JDCPEKQWFDWQLI-LUQKBWBOSA-N
InChI=1S/C53H90O22/c1-23(2)10-9-14-53(8,75-47-43(67)39(63)37(61)29(72-47)22-68-45-41(65)36(60)28(21-56)69-45)24-11-16-52(7)33(24)25(57)18-31-50(5)15-13-32(49(3,4)30(50)12-17-51(31,52)6)73-48-44(40(64)35(59)27(20-55)71-48)74-46-42(66)38(62)34(58)26(19-54)70-46/h10,24-48,54-67H,9,11-22H2,1-8H3/t24-,25+,26+,27+,28-,29+,30-,31+,32-,33-,34+,35+,36-,37+,38-,39-,40-,41+,42+,43+,44+,45+,46-,47-,48-,50-,51+,52+,53-/m0/s1
Molecular Formula | C53H90O22 |
Molecular Weight | 1079.2685 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 29 / 29 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/27109153Curator's Comment: Description was created based on several sources, including https://www.lktlabs.com/product/ginsenoside-rc/
https://www.ncbi.nlm.nih.gov/pubmed/26981165
Sources: https://www.ncbi.nlm.nih.gov/pubmed/27109153
Curator's Comment: Description was created based on several sources, including https://www.lktlabs.com/product/ginsenoside-rc/
https://www.ncbi.nlm.nih.gov/pubmed/26981165
Ginsenoside Rc is a triterpene saponin originally found in species of Panax that exhibits antioxidative, anti-aging, antinociceptive, and anti-diabetic activities. Ginsenoside Rc inhibits phosphorylation of Foxo1, inhibits AMPK, activates PI3K/Akt signaling, and increases levels of catalase, decreasing oxidative stress. Ginsenoside Rc also induces antinociception in animal models of writhing and formalin-induced pain, potentially through activity on transient receptor potential vanilloid 1 (TRPV1) channels. In other animal models, ginsenoside Rc activates AMPK and p38 MAPK, increasing glucose uptake. Additionally, this compound increases the life span of Caenorhabditis elegans. Ginsenoside Rc has being shown to attenuate inflammatory symptoms in CIA, EtOH/HCl-mediated gastritis, and LPS/D-galactosamine (D-GalN)-triggered hepatitis without altering toxicological parameters, and without inducing gastric irritation. These anti-inflammatory effects were accompanied by the suppression of TNF-a and IL-6 production and the induction of anti-inflammatory cytokine IL-10 in mice with CIA. Ginsenoside Rc also attenuated the increased levels of luciferase activity by IRF-3 and AP-1, reduced TBK1, IRF-3, and ATF2 phosphorylation in the joint and liver tissues of mice with hepatitis. Ginsenoside Rc may be a major component of Korean Red Ginseng, marketed in Korea, with useful anti-inflammatory properties due to its suppression of IRF-3 and AP-1 pathways. Korean ginseng (Panax ginseng Meyer, Araliaceae) is traditionally used as an important herbal medicine in Far East Asia. Korean Red Ginseng is possibly effective for:
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: Activator protein-1 signaling pathway Sources: https://www.ncbi.nlm.nih.gov/pubmed/27109153 |
|||
Target ID: CHEMBL4506 Sources: https://www.ncbi.nlm.nih.gov/pubmed/26981165 |
|||
Target ID: GO:0060612 Sources: https://www.ncbi.nlm.nih.gov/pubmed/25594343 |
|||
Target ID: CHEMBL280 Sources: https://www.ncbi.nlm.nih.gov/pubmed/24384406 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
PubMed
Title | Date | PubMed |
---|---|---|
Purification and characterization of new special ginsenosidase hydrolyzing multi-glycisides of protopanaxadiol ginsenosides, ginsenosidase type I. | 2007 Feb |
|
Molecular mechanisms governing different pharmacokinetics of ginsenosides and potential for ginsenoside-perpetrated herb-drug interactions on OATP1B3. | 2015 Feb |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://clinicaltrials.gov/ct2/show/NCT02204826
KRG extract contained 1.80mg/g Ginsenoside Rc, as well as ginsenoside-Rb1: 4.26mg/g, -B2: 1.71 mg/g, -Rb2: 1.62mg/g, -Rd: 0.29mg/g, -Rf: 0.67mg/g, -Rg1: 2.61mg/g, -Rg2: 0.20mg/g, -Rg3: 0.13mg/g, and other minor ginsenosides. During the study period, three capsules (500 mg/dose) were taken daily for 12 weeks
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/24384406
Ginsenoside Rc inhibits MMP-13 expression in IL-1β-treated SW1353 cells at non-cytotoxic concentration (30 uM).
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 08:02:59 GMT 2023
by
admin
on
Sat Dec 16 08:02:59 GMT 2023
|
Record UNII |
0K83B0L786
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
310104
Created by
admin on Sat Dec 16 08:03:00 GMT 2023 , Edited by admin on Sat Dec 16 08:03:00 GMT 2023
|
PRIMARY | |||
|
12855889
Created by
admin on Sat Dec 16 08:03:00 GMT 2023 , Edited by admin on Sat Dec 16 08:03:00 GMT 2023
|
PRIMARY | |||
|
234-253-5
Created by
admin on Sat Dec 16 08:03:00 GMT 2023 , Edited by admin on Sat Dec 16 08:03:00 GMT 2023
|
PRIMARY | |||
|
0K83B0L786
Created by
admin on Sat Dec 16 08:03:00 GMT 2023 , Edited by admin on Sat Dec 16 08:03:00 GMT 2023
|
PRIMARY | |||
|
77154
Created by
admin on Sat Dec 16 08:03:00 GMT 2023 , Edited by admin on Sat Dec 16 08:03:00 GMT 2023
|
PRIMARY | |||
|
DTXSID60911542
Created by
admin on Sat Dec 16 08:03:00 GMT 2023 , Edited by admin on Sat Dec 16 08:03:00 GMT 2023
|
PRIMARY | |||
|
11021-14-0
Created by
admin on Sat Dec 16 08:03:00 GMT 2023 , Edited by admin on Sat Dec 16 08:03:00 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> CONSTITUENT ALWAYS PRESENT |
USP
|
||
|
PARENT -> CONSTITUENT ALWAYS PRESENT |
USP
|
||
|
PARENT -> CONSTITUENT ALWAYS PRESENT |
USP
|